John Madigan - Gilead Sciences Independent Director
GILD Stock | USD 66.76 0.60 0.91% |
Director
Mr. John W. Madigan is an Independent Director of Gilead Sciences Inc. He is the retired Chairman and Chief Executive Officer of Tribune Company and a director and former Chairman of the Robert R. McCormick Foundation. Mr. Madigan is also a former member of the Defense Business Board of the Department of Defense, a former advisor to Madison Dearborn Partners and a director and former Chairman of The Chicago Council on Global Affairs. He previously served as a director of ATT Wireless, Boise Cascade Holdings, L.L.C. and Morgan Stanley. He serves as a trustee of Northwestern University and Rush University Medical Center. Mr. Madigan is a member and former Chairman of The Commercial Club of Chicago and a director of New Schools for Chicago. since 2005.
Age | 77 |
Tenure | 19 years |
Address | 333 Lakeside Drive, Foster City, CA, United States, 94404 |
Phone | 650 574 3000 |
Web | https://www.gilead.com |
Gilead Sciences Management Efficiency
The company has return on total asset (ROA) of 0.0978 % which means that it generated a profit of $0.0978 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2554 %, meaning that it created $0.2554 on every $100 dollars invested by stockholders. Gilead Sciences' management efficiency ratios could be used to measure how well Gilead Sciences manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to 0.22. The current year's Return On Capital Employed is expected to grow to 0.19. At present, Gilead Sciences' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 5.9 B, whereas Total Current Assets are forecasted to decline to about 10.8 B.Similar Executives
Showing other executives | DIRECTOR Age | ||
Marc Dunoyer | AstraZeneca PLC ADR | 72 | |
Sanders Williams | Amgen Inc | 69 | |
Gregory Garland | Amgen Inc | 60 | |
Glenn Tilton | AbbVie Inc | 72 | |
Francois Carbonnel | Amgen Inc | 69 | |
Christine Seidman | Merck Company | 68 | |
Karen Vousden | Bristol Myers Squibb | 63 | |
Bruce Burlington | AstraZeneca PLC ADR | 67 | |
Thomas Cech | Merck Company | 72 | |
Raul Alvarez | Eli Lilly and | 65 | |
James Kilts | Pfizer Inc | 71 | |
Karen Walker | Eli Lilly and | 59 | |
Jackson Tai | Eli Lilly and | 71 | |
Erik Fyrwald | Eli Lilly and | 58 | |
Wendell Weeks | Merck Company | 59 | |
Frederick Waddell | AbbVie Inc | 67 | |
Charles Prince | Johnson Johnson | 71 | |
Anne Mulcahy | Johnson Johnson | 68 | |
Gabrielle Sulzberger | Eli Lilly and | 60 | |
Hubert Joly | Johnson Johnson | 61 | |
Mark Weinberger | Johnson Johnson | 59 |
Management Performance
Return On Equity | 0.26 | ||||
Return On Asset | 0.0978 |
Gilead Sciences Leadership Team
Elected by the shareholders, the Gilead Sciences' board of directors comprises two types of representatives: Gilead Sciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Gilead. The board's role is to monitor Gilead Sciences' management team and ensure that shareholders' interests are well served. Gilead Sciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Gilead Sciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
Kathleen Watson, Executive Vice President - Human Resources | ||
John McHutchison, Executive Vice President - Clinical Research | ||
Andrew Cheng, Executive Vice President - HIV Therapeutics and Development Operations | ||
John Martin, Chairman and CEO | ||
Andrew Dickinson, Executive Vice President - Corporate Development and Strategy | ||
Michael Quigley, VP Biology | ||
Linda Higgins, Innovation Research | ||
Gayle Wilson, Independent Director | ||
Daniel ODay, Chairman of the Board, CEO | ||
Jacqueline Barton, Director | ||
Brett Pletcher, Executive VP and General Counsel | ||
William Lee, Executive Vice President - Research | ||
Deborah Telman, General Affairs | ||
John Madigan, Independent Director | ||
Martin Silverstein, Executive Vice President - Strategy | ||
Kevin Lofton, Independent Director | ||
Jacquie CFA, Vice Relations | ||
Paul Carter, Executive Vice President - Commercial Operations | ||
Gregg Alton, Executive VP of Corporate and Medical Affairs and Secretary | ||
Diana Brainard, Senior Vice President HIV and Emerging Viral Infections | ||
Flavius MD, Executive Research | ||
Carla Hills, Independent Director | ||
John Cogan, Lead Independent Director | ||
Sandra Patterson, Corporate VP | ||
John Milligan, Pres and COO | ||
Nicholas Moore, Independent Director | ||
James Meyers, Executive Vice President - Worldwide Commercial Operations | ||
Katie Watson, Executive Vice President of Human Resources | ||
Kelly Kramer, Director | ||
Johanna Mercier, Chief Commercial Officer | ||
Jyoti Mehra, Executive Vice President of Human Resources | ||
Laura Hamill, Executive Vice President - Worldwide Commercial Operations | ||
Robin Washington, CFO and Executive VP | ||
Norbert Bischofberger, Chief Scientific Officer and Executive VP of RandD | ||
Per WoldOlsen, Independent Director | ||
Harish Manwani, Director | ||
Taiyin Yang, Executive Vice President - Pharmaceutical Development and Manufacturing | ||
Kevin Young, COO | ||
Etienne Davignon, Independent Director | ||
Richard Whitley, Independent Director | ||
Diane Wilfong, Corp VP | ||
Rudolf Ertl, Canada, Australia |
Gilead Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Gilead Sciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.26 | ||||
Return On Asset | 0.0978 | ||||
Profit Margin | 0.21 % | ||||
Operating Margin | 0.42 % | ||||
Current Valuation | 99.64 B | ||||
Shares Outstanding | 1.25 B | ||||
Shares Owned By Institutions | 88.30 % | ||||
Number Of Shares Shorted | 22.57 M | ||||
Price To Earning | 359.42 X | ||||
Price To Book | 3.72 X |
Gilead Sciences Investors Sentiment
The influence of Gilead Sciences' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Gilead. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Gilead Sciences' public news can be used to forecast risks associated with an investment in Gilead. The trend in average sentiment can be used to explain how an investor holding Gilead can time the market purely based on public headlines and social activities around Gilead Sciences. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Gilead Sciences' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Gilead Sciences' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Gilead Sciences' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Gilead Sciences.
Gilead Sciences Implied Volatility | 37.96 |
Gilead Sciences' implied volatility exposes the market's sentiment of Gilead Sciences stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Gilead Sciences' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Gilead Sciences stock will not fluctuate a lot when Gilead Sciences' options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Gilead Sciences in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Gilead Sciences' short interest history, or implied volatility extrapolated from Gilead Sciences options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gilead Sciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Complementary Tools for Gilead Stock analysis
When running Gilead Sciences' price analysis, check to measure Gilead Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gilead Sciences is operating at the current time. Most of Gilead Sciences' value examination focuses on studying past and present price action to predict the probability of Gilead Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gilead Sciences' price. Additionally, you may evaluate how the addition of Gilead Sciences to your portfolios can decrease your overall portfolio volatility.
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is Gilead Sciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Gilead Sciences. If investors know Gilead will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Gilead Sciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.13) | Dividend Share 3 | Earnings Share 4.5 | Revenue Per Share 21.728 | Quarterly Revenue Growth (0.04) |
The market value of Gilead Sciences is measured differently than its book value, which is the value of Gilead that is recorded on the company's balance sheet. Investors also form their own opinion of Gilead Sciences' value that differs from its market value or its book value, called intrinsic value, which is Gilead Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Gilead Sciences' market value can be influenced by many factors that don't directly affect Gilead Sciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Gilead Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Gilead Sciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Gilead Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.